These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications. Kim SY; Yang EG Molecules; 2015 Nov; 20(11):20551-68. PubMed ID: 26610437 [TBL] [Abstract][Full Text] [Related]
11. Prolyl-hydroxylase inhibition preserves endothelial cell function in a rat model of vascular ischemia reperfusion injury. Barnucz E; Veres G; Hegedűs P; Klein S; Zöller R; Radovits T; Korkmaz S; Horkay F; Merkely B; Karck M; Szabó G J Pharmacol Exp Ther; 2013 Apr; 345(1):25-31. PubMed ID: 23388095 [TBL] [Abstract][Full Text] [Related]
13. HIF-1α activation results in actin cytoskeleton reorganization and modulation of Rac-1 signaling in endothelial cells. Weidemann A; Breyer J; Rehm M; Eckardt KU; Daniel C; Cicha I; Giehl K; Goppelt-Struebe M Cell Commun Signal; 2013 Oct; 11():80. PubMed ID: 24144209 [TBL] [Abstract][Full Text] [Related]
14. Endurance training prevents negative effects of the hypoxia mimetic dimethyloxalylglycine on cardiac and skeletal muscle function. Favier FB; Britto FA; Ponçon B; Begue G; Chabi B; Reboul C; Meyer G; Py G J Appl Physiol (1985); 2016 Feb; 120(4):455-63. PubMed ID: 26679609 [TBL] [Abstract][Full Text] [Related]
15. Prolyl hydroxylation regulates protein degradation, synthesis, and splicing in human induced pluripotent stem cell-derived cardiomyocytes. Stoehr A; Yang Y; Patel S; Evangelista AM; Aponte A; Wang G; Liu P; Boylston J; Kloner PH; Lin Y; Gucek M; Zhu J; Murphy E Cardiovasc Res; 2016 Jun; 110(3):346-58. PubMed ID: 27095734 [TBL] [Abstract][Full Text] [Related]
16. The role of HIF in cobalt-induced ischemic tolerance. Jones SM; Novak AE; Elliott JP Neuroscience; 2013 Nov; 252():420-30. PubMed ID: 23916558 [TBL] [Abstract][Full Text] [Related]
17. Dynamics of Prolyl Hydroxylases Levels During Disease Progression in Experimental Colitis. Bakshi HA; Mishra V; Satija S; Mehta M; Hakkim FL; Kesharwani P; Dua K; Chellappan DK; Charbe NB; Shrivastava G; Rajeshkumar S; Aljabali AA; Al-Trad B; Pabreja K; Tambuwala MM Inflammation; 2019 Dec; 42(6):2032-2036. PubMed ID: 31377947 [TBL] [Abstract][Full Text] [Related]
18. Effects of prolyl-hydroxylase inhibition and chronic intermittent hypoxia on synaptic transmission and plasticity in the rat CA1 and dentate gyrus. Wall AM; Corcoran AE; O'Halloran KD; O'Connor JJ Neurobiol Dis; 2014 Feb; 62():8-17. PubMed ID: 24055213 [TBL] [Abstract][Full Text] [Related]
19. Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection. Requena-Ibáñez JA; Santos-Gallego CG; Rodriguez-Cordero A; Zafar MU; Badimon JJ Cardiovasc Drugs Ther; 2022 Dec; 36(6):1187-1196. PubMed ID: 34533692 [TBL] [Abstract][Full Text] [Related]
20. High Glucose Activates Prolyl Hydroxylases and Disrupts HIF-α Signaling via the P53/TIGAR Pathway in Cardiomyocyte. Chen JX; Li L; Cantrell AC; Williams QA; Zeng H Cells; 2023 Mar; 12(7):. PubMed ID: 37048134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]